Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Clinical Trial.
Jesus D Gonzalez-LugoSuman KambhampatiAbdulraheem YacoubWilliam B DonnellanJesus G BerdejaPrafulla BhagatKaren FehnCassady RemySakshi JasraMohammed KazemiKith PradhanMimi Y KimIoannis MantzarisR Alejandro SicaNishi ShahMendel GoldfingerNoah KornblumKira GritsmanIra BraunschweigUlrich SteidlBritta WillAditi ShastriAmit K VermaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
ELT and LEN are well tolerated and effective in achieving hematological improvement in patients with low/intermediate-risk MDS.